Neogen Corporation (NEOG) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Large impairment ⢠Improving cashflow NEOG has solid liquidity and gross margins but a $1.092B FY2025 nonâcash impairment left returns weak and valuation unclear despite improving quarterly EBITDA and positive FCF.
Price Behavior
Key Price Behavior Insights: ⢠Slight upward bias ⢠Rangebound volatility ⢠Resistance capped Support Level: $9.10â$9.40 (deeper $8.36) Resistance Level: $10.30â$10.40 Slight upward bias: last month SMA â $9.24 and 2026-04-10 close $9.42 with price trading $8.36â$10.34, support forming at $9.10â$9.40 (deeper $8.36) and resistance around $10.30â$10.40âabove $10.40 would resume upside, below $8.40â$8.80 would confirm a larger downtrend.
Sentiment & News
Key News Insights: ⢠Earnings beat ⢠Margin decline ⢠Institutional buying Neogen beat Q3 estimates and raised guidance but falling gross margins and Animal Safety weakness, despite strategic progress and large institutional buys, pressured the stock.
AI Summary
NEOG is no longer a pure consumables growth story but a turnaround/rescue trade where nearâterm value depends on successful execution of the manufacturing/supplyâchain transition and timely completion of the $160M genomics sale to drive margin recovery and deleveraging. Monitor normalized gross margins (back toward ~47%+), sustained positive free cash flow, and sale timingâmisses or further inventory/impairments materially increase downside risk.
Description
Neogen Corporation develops, manufactures and sells products used to detect, mitigate and monitor biological, chemical and sanitary hazards across the food and animal sectors. Its Food Safety business supplies diagnostic test kits and sanitation assays to food and feed producers, processors, grain handlers, dairies, laboratories and related manufacturers to identify pathogens, toxins, residues, allergens and other contaminants, while its Animal Safety business provides veterinary medicines, vaccines, diagnostic tools, disinfectants and genomics services, including drug-residue and toxicology testing for animals. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | NEOG | Neogen Corporation | Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential. | Closed | +38.9% |